<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871375</url>
  </required_header>
  <id_info>
    <org_study_id>CLE914-P001</org_study_id>
    <nct_id>NCT02871375</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of DAILIES TOTAL1® (DT1) Multifocal</brief_title>
  <official_title>DAILIES TOTAL1® Multifocal Clinical Assessment in Challenging Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate DAILIES TOTAL1® Multifocal (DTl MF) contact lenses
      in current multifocal contact lens wearers with symptoms of end of day discomfort compared to
      their habitual multifocal contact lens correction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 30, 2016</start_date>
  <completion_date type="Actual">November 14, 2016</completion_date>
  <primary_completion_date type="Actual">November 14, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm)</measure>
    <time_frame>Day 14, each product</time_frame>
    <description>Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HC/HI VA was assessed binocularly (both eyes together) at 80 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR). A lower logMAR value indicates better visual acuity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score</measure>
    <time_frame>Day 14, each product</time_frame>
    <description>The abbreviated CLDEQ-8 is an 8-item questionnaire used to assess comfort and dryness. Total CLDEQ-8 score ranged from 0 to 37, where a lower score represented less symptomology.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>DT1 MF, then Habitual</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual, then DT1 MF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delefilcon A multifocal contact lenses</intervention_name>
    <description>Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)</description>
    <arm_group_label>DT1 MF, then Habitual</arm_group_label>
    <arm_group_label>Habitual, then DT1 MF</arm_group_label>
    <other_name>DAILIES TOTAL1® multifocal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Habitual multifocal contact lenses</intervention_name>
    <description>Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality</description>
    <arm_group_label>DT1 MF, then Habitual</arm_group_label>
    <arm_group_label>Habitual, then DT1 MF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must sign an informed consent document;

          -  Current daily wearer of soft multifocal contact lenses for at least 6 months with
             symptoms of contact lens discomfort as defined by the prescreening Eligibility
             Questionnaire;

          -  Requires a near spectacle add of +0.50 to +2.50 diopters (D) (inclusive);

          -  Requires lenses within the power range of study lenses to be fitted;

          -  Best corrected VA (BCVA) of 20/30 (0.2 logarithmic minimum angle of resolution
             [logMAR]) or better in each eye at distance;

          -  Willing to wear study lenses for a minimum of 5 days per week, 6 hours per day, and
             attend all study visits;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Any eye condition that contraindicates wearing contact lenses as determined by the
             Investigator;

          -  Any use of medications for which contact lens wear could be contraindicated, as
             determined by the Investigator;

          -  Monocular (only one eye functional) or fit with only 1 lens;

          -  Fitted with monovision;

          -  Prior refractive surgery (e.g., laser vision correction, photorefractive keratectomy,
             etc.);

          -  History of herpetic keratitis, ocular surgery, or irregular cornea;

          -  Currently wearing DT1 MF contact lenses;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Project Manager, PLS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>October 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 24, 2017</results_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myopia</keyword>
  <keyword>presbyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 11 study centers located in the United States.</recruitment_details>
      <pre_assignment_details>Of the 170 enrolled, 2 subjects were exited as screen failures prior to randomization. An additional 2 subjects were randomized in error but not exposed. This reporting group includes all randomized and exposed subjects (166).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DT1 MF / Habitual MF</title>
          <description>Delefilcon A multifocal (MF) contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.</description>
        </group>
        <group group_id="P2">
          <title>Habitual MF / DT1 MF</title>
          <description>Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, First 14 Days of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inclusion criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2, Second 14 Days of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all randomized subjects who were exposed to any study lenses, except for lenses used for parameter optimization and fitting (Full Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>Delefilcon A multifocal contact lenses and subject's habitual multifocal contact lenses worn bilaterally during Period 1 and Period 2 in a crossover assignment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Binocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm)</title>
        <description>Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HC/HI VA was assessed binocularly (both eyes together) at 80 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR). A lower logMAR value indicates better visual acuity.</description>
        <time_frame>Day 14, each product</time_frame>
        <population>Full Analysis Set. Number Analyzed is the number of subjects with non-missing responses.</population>
        <group_list>
          <group group_id="O1">
            <title>DT1 MF</title>
            <description>Delefilcon A multifocal contact lenses worn bilaterally for 14 ± 3 days in Period 1 and Period 2</description>
          </group>
          <group group_id="O2">
            <title>Habitual MF</title>
            <description>Subject's habitual multifocal contact lenses worn bilaterally for 14 ± 3 days in Period 1 and Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm)</title>
          <description>Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HC/HI VA was assessed binocularly (both eyes together) at 80 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR). A lower logMAR value indicates better visual acuity.</description>
          <population>Full Analysis Set. Number Analyzed is the number of subjects with non-missing responses.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.10"/>
                    <measurement group_id="O2" value="-0.09" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score</title>
        <description>The abbreviated CLDEQ-8 is an 8-item questionnaire used to assess comfort and dryness. Total CLDEQ-8 score ranged from 0 to 37, where a lower score represented less symptomology.</description>
        <time_frame>Day 14, each product</time_frame>
        <population>Full Analysis Set. Number Analyzed is the number of subjects with non-missing responses.</population>
        <group_list>
          <group group_id="O1">
            <title>DT1 MF</title>
            <description>Delefilcon A multifocal contact lenses worn bilaterally for 14 ± 3 days in Period 1 and Period 2</description>
          </group>
          <group group_id="O2">
            <title>Habitual MF</title>
            <description>Subject's habitual multifocal contact lenses worn bilaterally for 14 ± 3 days in Period 1 and Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score</title>
          <description>The abbreviated CLDEQ-8 is an 8-item questionnaire used to assess comfort and dryness. Total CLDEQ-8 score ranged from 0 to 37, where a lower score represented less symptomology.</description>
          <population>Full Analysis Set. Number Analyzed is the number of subjects with non-missing responses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period One</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="5.4"/>
                    <measurement group_id="O2" value="17.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period Two</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="6.3"/>
                    <measurement group_id="O2" value="13.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="5.9"/>
                    <measurement group_id="O2" value="14.9" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from time of consent for the duration of a subject’s participation in the study (up to 44 days). AEs are reported as pre-treatment and treatment-emergent.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users, or other persons, whether or not related to the investigational medical device (test article). AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre-treatment</title>
          <description>All subjects who consented to participate in the study prior to exposure to study lenses dispensed for 14-day wear</description>
        </group>
        <group group_id="E2">
          <title>DT1 MF</title>
          <description>Delefilcon A multifocal contact lenses worn bilaterally for 14 ± 3 days in Period 1 and Period 2</description>
        </group>
        <group group_id="E3">
          <title>Habitual MF</title>
          <description>Subject's habitual multifocal contact lenses worn bilaterally for 14 ± 3 days in Period 1 and Period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Franchise Head, Vision Care</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

